The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Morphoproteomics of VEGF pathway mediators as evidence of reversible resistance to VEGF-TKIs demonstrated by expression of activated ERK and STAT3 in metastatic renal cell carcinoma (mRCC).
Shan Guo
No relevant relationships to disclose
Swetha Siddappa Yadav
No relevant relationships to disclose
Jamie Buryanek
No relevant relationships to disclose
Robert E Brown
No relevant relationships to disclose
Fangqian Ouyang
No relevant relationships to disclose
Robert J. Amato
No relevant relationships to disclose